Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Neuromuscular Blockade Reversal in Children
NCT05724550Completed
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Diaphragm excursion ratio. Started Feb 2023; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT05724550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724550.